Literature DB >> 21113605

[Class I antiarrhythmic drugs: mechanisms, contraindications, and current indications].

C Pott1, D G Dechering, A Muszynski, S Zellerhoff, A Bittner, K Wasmer, G Mönnig, L Eckardt.   

Abstract

Class I antiarrhythmic drugs are sodium channel inhibitors that act by slowing myocardial conduction and, thus, interrupting or preventing reentrant arrhythmia. Due to proarrhythmic effects and the risk of ventricular tachyarrhythmia, class I antiarrhythmics should not be administered in patients with structural heart disease. Nevertheless, there remains a broad spectrum of arrhythmias--among the most common being atrial fibrillation--that can successfully be treated with class I antiarrhythmic drugs. This review gives an overview on the classification, antiarrhythmic mechanisms, indications, side effects, and application modes of class I antiarrhythmic drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21113605     DOI: 10.1007/s00399-010-0090-1

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  47 in total

Review 1.  Cellular basis of triggered arrhythmias in heart failure.

Authors:  Steven M Pogwizd; Donald M Bers
Journal:  Trends Cardiovasc Med       Date:  2004-02       Impact factor: 6.677

Review 2.  Approach to wide complex tachycardias in patients without structural heart disease.

Authors:  L Eckardt; G Breithardt; P Kirchhof
Journal:  Heart       Date:  2006-05       Impact factor: 5.994

3.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

4.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.

Authors:  Douglas P Zipes; A John Camm; Martin Borggrefe; Alfred E Buxton; Bernard Chaitman; Martin Fromer; Gabriel Gregoratos; George Klein; Arthur J Moss; Robert J Myerburg; Silvia G Priori; Miguel A Quinones; Dan M Roden; Michael J Silka; Cynthia Tracy; Jean-Jacques Blanc; Andrzej Budaj; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Elliott M Antman; Jeffrey L Anderson; Sharon A Hunt; Jonathan L Halperin; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Eur Heart J       Date:  2006-09       Impact factor: 29.983

5.  Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation.

Authors:  I A Khan
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

Review 6.  Amiodarone: a multifaceted antiarrhythmic drug.

Authors:  Bramah N Singh
Journal:  Curr Cardiol Rep       Date:  2006-09       Impact factor: 2.931

7.  Effect of the antiarrhythmic agent flecainide acetate on acute and chronic pacing thresholds.

Authors:  K J Hellestrand; P J Burnett; J R Milne; R S Bexton; A W Nathan; A J Camm
Journal:  Pacing Clin Electrophysiol       Date:  1983-09       Impact factor: 1.976

8.  A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group.

Authors: 
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

9.  Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.

Authors:  Hiroshi Watanabe; Nagesh Chopra; Derek Laver; Hyun Seok Hwang; Sean S Davies; Daniel E Roach; Henry J Duff; Dan M Roden; Arthur A M Wilde; Björn C Knollmann
Journal:  Nat Med       Date:  2009-03-29       Impact factor: 53.440

10.  The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol.

Authors:  Sascha Rolf; Hans-Jürgen Bruns; Thomas Wichter; Paulus Kirchhof; Michael Ribbing; Kristina Wasmer; Matthias Paul; Günter Breithardt; Wilhelm Haverkamp; Lars Eckardt
Journal:  Eur Heart J       Date:  2003-06       Impact factor: 29.983

View more
  2 in total

1.  Analysis of Electrophysiological Mechanisms of N-Deacetyllapaconitine Monochlorhydrate, the Main Metabolite of Lappaconitine Hydrobromide.

Authors:  I B Tsorin; I Yu Teplov; V P Zinchenko; M B Vititnova; E M Tsyrlina; M S Yunusov; S A Kryzhanovskii
Journal:  Bull Exp Biol Med       Date:  2022-06-24       Impact factor: 0.804

2.  New Progress in Understanding the Cellular Mechanisms of Anti-arrhythmic Drugs.

Authors:  Zhe An; Guang Yang; Xuanxuan Liu; Zhongfan Zhang; Guohui Liu
Journal:  Open Life Sci       Date:  2018-09-22       Impact factor: 0.938

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.